Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NT-175

Cell therapy (TCR-T) · Kills target cells, directed at TP53 R175H mutant (TP53) · developed by AstraZeneca

Phase 1 Most advanced trial

AZN Developer

1 Registered trials

What is NT-175?

NT-175 is an autologous T-cell receptor (TCR) engineered T-cell therapy targeting the TP53 R175H mutation. After ex vivo expansion, the engineered T cells recognize and kill tumor cells expressing this p53 mutant. It is being studied in multiple solid tumors and hematologic malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (TCR-T)
Targets: TP53 R175H mutant (TP53) (antigen), HLA-A*02:01 (binding partner it blocks)
Mechanism: Kills target cells, directed at TP53 R175H mutant (TP53)
Pathways: apoptosis
Therapy area: Oncology
Developer: AstraZeneca (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05877599	Phase 1	Non-small Cell Lung Cancer	Recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerColorectal CarcinomaHead and Neck Squamous Cell CarcinomaMyeloid Neoplasms (AML/MDS)Non-small Cell Lung CancerOther Solid TumorsOvarian CancerPancreatic Adenocarcinoma

Other drugs acting on TP53

APR-548 Phase 1 Eprenetapopt Phase 3

More from AstraZeneca

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind NT-175

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z